ATE275967T1 - Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie - Google Patents
Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämieInfo
- Publication number
- ATE275967T1 ATE275967T1 AT01900978T AT01900978T ATE275967T1 AT E275967 T1 ATE275967 T1 AT E275967T1 AT 01900978 T AT01900978 T AT 01900978T AT 01900978 T AT01900978 T AT 01900978T AT E275967 T1 ATE275967 T1 AT E275967T1
- Authority
- AT
- Austria
- Prior art keywords
- exendins
- hypertriglyceridemia
- agonists
- treatment
- exendin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17536500P | 2000-01-10 | 2000-01-10 | |
PCT/US2001/000719 WO2001051078A1 (en) | 2000-01-10 | 2001-01-09 | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE275967T1 true ATE275967T1 (de) | 2004-10-15 |
Family
ID=22639978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01900978T ATE275967T1 (de) | 2000-01-10 | 2001-01-09 | Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie |
Country Status (12)
Country | Link |
---|---|
US (1) | US20030036504A1 (de) |
EP (1) | EP1246638B2 (de) |
JP (1) | JP2003519667A (de) |
AT (1) | ATE275967T1 (de) |
AU (1) | AU2006202247A1 (de) |
CA (1) | CA2396157A1 (de) |
DE (1) | DE60105547T3 (de) |
DK (1) | DK1246638T4 (de) |
ES (1) | ES2227115T5 (de) |
HK (1) | HK1050477A1 (de) |
PT (1) | PT1246638E (de) |
WO (1) | WO2001051078A1 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1629849B2 (de) * | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmazeutische Zusammensetzungen enthaltend Exendine und deren Agonisten |
US20030040469A1 (en) * | 2000-03-08 | 2003-02-27 | Knudsen Liselotte Bjerre | Lowering serum lipids |
AU2001237254A1 (en) * | 2000-03-08 | 2001-09-17 | Novo-Nordisk A/S | Lowering serum lipids |
WO2003011892A2 (en) | 2001-07-31 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1 exendin-4 peptide analogs and uses thereof |
US7459432B2 (en) | 2001-09-24 | 2008-12-02 | Imperial College Innovations Ltd. | Modification of feeding behavior |
WO2003057235A2 (en) | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Modification of feeding behavior |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
EP1789440A4 (de) | 2004-02-11 | 2008-03-12 | Amylin Pharmaceuticals Inc | Pankreas-polypeptidfamilienmotive und diese enthaltende polypeptide |
DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US20090286723A1 (en) * | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
US20060190425A1 (en) * | 2005-02-24 | 2006-08-24 | Yuan-Chi Chang | Method for merging multiple ranked lists with bounded memory |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
US7452868B2 (en) * | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
NZ565535A (en) | 2005-06-30 | 2011-03-31 | Ipsen Pharma Sas | GLP-1 pharmaceutical compositions |
CN101296942A (zh) * | 2005-08-11 | 2008-10-29 | 安米林药品公司 | 具有可选择特性的杂合多肽 |
WO2007024700A2 (en) | 2005-08-19 | 2007-03-01 | Amylin Pharmaceuticals, Inc. | Exendin for treating diabetes and reducing body weight |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
CA2699255A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033687A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Spantide ii and bfgf (119-126) for therapeutic applications |
US20110263496A1 (en) | 2008-05-21 | 2011-10-27 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholesterol and triglycerides |
EP2303226B1 (de) | 2008-06-25 | 2016-03-23 | Endo Pharmaceuticals Solutions Inc. | Verlängerte freisetzung von exenatid und anderen polypeptiden |
WO2009158415A1 (en) | 2008-06-25 | 2009-12-30 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent |
EP2216042A1 (de) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP1-analoge pharmazeutische Zusammensetzungen |
US20120231022A1 (en) | 2009-05-28 | 2012-09-13 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
CA2803646A1 (en) | 2010-07-02 | 2012-01-05 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
JP2014504588A (ja) | 2010-12-22 | 2014-02-24 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 膵島細胞移植のためのglp−1受容体アゴニスト |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
SI2934567T1 (sl) | 2012-12-21 | 2018-10-30 | Sanofi | Derivati eksendina-4 kot dualni GLP1/GIP ali trigonalni agonisti GLP1/GIP/glukagon |
EP3080150B1 (de) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
MA44154A (fr) | 2015-12-23 | 2018-10-31 | Amgen Inc | Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 |
WO2018071528A1 (en) * | 2016-10-11 | 2018-04-19 | University Of Georgia Research Foundation, Inc. | Proteins and method for treating obesity and associated comorbidities |
EP3551202B1 (de) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren zur erhöhung der wirksamkeit von incretinbasierten arzneimitteln bei darauf angewiesenen personen |
CA3047862A1 (en) * | 2016-12-22 | 2018-06-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
PE20200013A1 (es) | 2017-06-20 | 2020-01-06 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 |
EP3934679A1 (de) | 2019-03-08 | 2022-01-12 | Amgen Inc. | Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998005331A2 (en) * | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
EP1629849B2 (de) * | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmazeutische Zusammensetzungen enthaltend Exendine und deren Agonisten |
IL134364A0 (en) * | 1997-12-12 | 2001-04-30 | Warner Lambert Co | ANTIHYPERLIPIDEMIC STATIN-LP (a) INHIBITOR COMBINATIONS |
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
JP2002544127A (ja) * | 1999-04-30 | 2002-12-24 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 修飾されたエキセンジンおよびエキセンジン・アゴニスト |
-
2001
- 2001-01-09 DK DK01900978.6T patent/DK1246638T4/da active
- 2001-01-09 ES ES01900978.6T patent/ES2227115T5/es not_active Expired - Lifetime
- 2001-01-09 JP JP2001551501A patent/JP2003519667A/ja active Pending
- 2001-01-09 DE DE60105547.0T patent/DE60105547T3/de not_active Expired - Lifetime
- 2001-01-09 AT AT01900978T patent/ATE275967T1/de active
- 2001-01-09 WO PCT/US2001/000719 patent/WO2001051078A1/en active IP Right Grant
- 2001-01-09 CA CA002396157A patent/CA2396157A1/en not_active Abandoned
- 2001-01-09 US US09/756,690 patent/US20030036504A1/en not_active Abandoned
- 2001-01-09 EP EP01900978.6A patent/EP1246638B2/de not_active Expired - Lifetime
- 2001-01-09 PT PT01900978T patent/PT1246638E/pt unknown
-
2003
- 2003-04-04 HK HK03102440A patent/HK1050477A1/xx not_active IP Right Cessation
-
2006
- 2006-05-26 AU AU2006202247A patent/AU2006202247A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1050477A1 (en) | 2003-06-27 |
DE60105547T2 (de) | 2005-10-13 |
DE60105547D1 (de) | 2004-10-21 |
WO2001051078A1 (en) | 2001-07-19 |
AU784488B2 (en) | 2006-04-13 |
DK1246638T4 (da) | 2014-09-22 |
CA2396157A1 (en) | 2001-07-19 |
EP1246638B1 (de) | 2004-09-15 |
AU2006202247A1 (en) | 2006-06-22 |
ES2227115T3 (es) | 2005-04-01 |
JP2003519667A (ja) | 2003-06-24 |
PT1246638E (pt) | 2004-12-31 |
US20030036504A1 (en) | 2003-02-20 |
DE60105547T3 (de) | 2014-12-31 |
DK1246638T3 (da) | 2005-01-10 |
EP1246638B2 (de) | 2014-07-30 |
EP1246638A1 (de) | 2002-10-09 |
ES2227115T5 (es) | 2014-10-30 |
AU2638001A (en) | 2001-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE275967T1 (de) | Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie | |
ATE367169T1 (de) | Verwendung von exendins und deren agonisten zur behandlung von schwangerschaftsdiabetes | |
DE602005019856D1 (de) | Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
ATE514418T1 (de) | Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan | |
ATE554800T1 (de) | Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe | |
TW200735890A (en) | Compositions and methods for increasing insulin sensitivity | |
MA30768B1 (fr) | Methodes d'administration d'agents hypoglycemiques a longue duree d'action | |
EA200400482A1 (ru) | Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран | |
UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
AR058892A1 (es) | Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina | |
UA82979C2 (ru) | Фармацевтическая композиция, пригодная для перорального введения, которая содержит no-высвобождающие нспвл, лекарственная форма, фармацевтическая комбинация и способы лечения | |
AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
EA200701751A1 (ru) | Улучшенные составы фенофибрата | |
EA200701750A1 (ru) | Улучшенные составы фенофибрата, содержащие ментол или пэг/полоксамер | |
HK1083296A1 (en) | Enteral composition for the prevention and/or treatment of sepsis | |
PT1001775E (pt) | Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil | |
WO2004052294A3 (en) | Compositions and methods related to lipid:emodin formulations | |
ATE399558T1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
AR040737A1 (es) | Administracion oral de calcitonina | |
ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
ATE412421T1 (de) | Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie | |
SE0303135D0 (sv) | Controlled food effect composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1246638 Country of ref document: EP |